Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic Heart Failure in China

 Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic Heart Failure in China

Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic Heart Failure in China

Shots:

  • The NDA submission was submitted to NMPA’s CDE and is based on P-III VICTORIA study, seeking regulatory approval of vericiguat in China
  • In Oct’2014, Bayer and MSD signed a WW agreement for sGC modulators. The therapy is being jointly developed by both the companies as per the collaboration and has received the US FDA’s PR in Jul’2020
  • Vericiguat (BAY 1021189/ MK-1242) is an sGC-stimulator being developed to treat patients with symptomatic CHF with an ejection fraction less than 45% who have had a previous worsening HF event in combination with available HF therapies

Click here ­to­ read full press release/ article | Ref: Bayer| Image: Berkeleyside

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post